Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Cloud – page 251

3 344 clinical trials in Saint-Cloud, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Cloud at a glance
3 344
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 344 trials in Saint-Cloud

Open in trial search

Colorectal adenocarcinoma+1

Not recruiting

Study of Romiplostim Treatment for Chemotherapy-induced Low Blood Platelets in Adults with Gastrointestinal, Pancreatic, or Colorectal Cancer Receiving Oxaliplatin Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim
  • Sponsor:Amgen Inc.

B-cell type acute leukaemia

Not recruiting

Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of TheraSphere, Durvalumab, and Tremelimumab for Patients with Liver Cancer (Hepatocellular Carcinoma)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Biocompatibles UK Limited

Dementia of the Alzheimer's type uncomplicated

Not recruiting

Study of XPro1595 for Patients with Early Alzheimer's Disease and Inflammation Markers

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Inmune Bio Inc.

Hepatocellular carcinoma

Not recruiting

Study on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone-refractory prostate cancer

Not recruiting

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

HIV infection

Not recruiting

Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Plasma cell myeloma

Not recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Patients with Untreated Multiple Myeloma Not Planning Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Hodgkin's disease

Not recruiting

Study of Pembrolizumab with Chemotherapy for Children and Young Adults with Classical Hodgkin Lymphoma Not Responding Well to Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Bleomycin
  • Sponsor:Merck Sharp & Dohme LLC

Migraine

Not recruiting

Study on Galcanezumab for Preventing Chronic Migraine in Adolescents Aged 12 to 17

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Galcanezumab
  • Sponsor:Eli Lilly & Co.

Portal hypertension

Not recruiting

Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BI 685509
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Arcus Biosciences Inc.

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Saint-Cloud

What the registry says about research in the country

01 Blood Cancer Research

Innovative trials focusing on lymphoma and multiple myeloma treatments, including studies of novel therapies like duvelisib for T-cell lymphoma and odronextamab for follicular lymphoma.

  • B-Cell Lymphomas
  • Multiple Myeloma
  • T-Cell Lymphomas

Several studies are evaluating combination therapies and comparing new treatment approaches against standard care.

02 Breast Cancer Studies

Comprehensive research into various types of breast cancer, with particular focus on hormone receptor-positive and triple-negative variants. Studies include early detection methods and novel therapeutic combinations.

  • HR+/HER2- Advanced Breast Cancer
  • Triple-Negative Breast Cancer
  • Early-Stage Disease

Trials incorporate innovative approaches like ctDNA monitoring and targeted therapies.

03 Advanced Cancer Therapies

Research focusing on targeted therapies for various advanced cancers, including studies of biliary tract cancer and non-small cell lung cancer treatments.

  • Lung Cancer
  • Biliary Tract Cancer
  • Prostate Cancer

Emphasis on immunotherapy combinations and precision medicine approaches.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.